Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space.
The tubeless insulin pump maker enrolls first patients in feasibility study to tests it artificial pancreas technology.
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.
As Medtronic prepares to begin the first U.S. trial of a low-glucose suspense system, and as diabetes device companies, researchers and advocates look to the U.S. Food and Drug Administration for guidance, one thing is obvious: The United States is way behind in giving patients access to the Holy Grail of type 1 diabetes treatment, […]
Morningstar analysts upgraded Insulet Corp.’s (NSDQ:PODD) credit rating from a CCC to a B- today, reflecting the company’s recent convertible debt offering, but the company will have to face off against medical device giant Medtronic Inc. (NYSE:MDT) in the insulin delivery market. Insulet announced a double offering of convertible senior notes and common stock late […]
Insulet Corp. (NSDQ:PODD) is hoping to win 510(k) clearance for a new Omnipod officials said will help the company reduce its production costs by more than a third. The latest version of the Omnipod insulin management system is one-third smaller, 25 percent lighter and “expected to reduce our cost of production by about a third, […]